Clinical Trial Search

Primary: Number of Participants That Experience One Year Relapse Free Survival After Undergoing Hematopoietic Stem Cell Transplant (HSCT) — 5 Participants

Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 12; 24; 14; 4 Participants

Primary: Maximum-tolerated Dose of Dinaciclib When Given in Combination With Ofatumumab, Defined as a Dose Level Where at Most One of 6 Evaluable Patients Has a Dose Limiting…

Primary: Recurrence-free Survival up to 60 Months — 9; 7; 2; 82 participants with an event

Primary: The Standardized Photosensitivity Range (SPR) in the Subject's Most Sensitive Eye Condition — 0.57; 1.38; 1.58; 6.80 Units on a scale

Primary: Percentage of Participants With a 50% or Greater Reduction in the Eczema Area and Severity Index (EASI 50) — 37; 57; 61 percentage of participants — p==0.065

Primary: Phase I - Dose-limiting Toxicity (DLT) — 0 DLT

Primary: Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 12 — 0.46; 0.18; -0.07; 0.01 Percentage of HbA1c — p=0.061

Primary: Aggregate Sedative Exposure During PCS Use (up to 5 Days). — 4; 3.5 units on a scale

Primary: Change From Baseline in Lactate Dehydrogenase — 1845.1; 398.7; -1446.4 Units/Liter — p=<0.0001

Primary: Change From Baseline in the Glycosylated Hemoglobin (HbA1c) at 12 Weeks — -0.457; -0.561; -0.428; -0.183 percentage of glycosylated hemoglobin

Primary: Pharmacokinetics (PK): Minimum Concentration (Cmin) of Ramucirumab — 32.9; 59.5; 69.3; 71.6 microgram per milliliter (µg/mL)

Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, and TEAEs Leading to Discontinuation — 43; 46; 46; 1 Participants

Primary: Number Participants With Adverse Events — 11; 3 Participants

Primary: Llocoregional Recurrence — 27 Participants